SEC Form 4 · accession 0001140361-18-001788
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan W Ayers
Officer — Chairman, President & CEO · Director
Period of report
Jan 9, 2018
Accepted (ET)
Jan 11, 2018 · 6:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 9, 2018 | M | 18,000 | $38.795 | A | 1,077,112 | D | |
| Common StockF1,F2 | Jan 9, 2018 | S | 14,300 | $165.0607 | D | 1,062,812 | D | |
| Common StockF1,F3 | Jan 9, 2018 | S | 3,700 | $165.4761 | D | 1,059,112 | D | |
| Common Stock | Jan 10, 2018 | M | 18,000 | $38.795 | A | 1,077,112 | D | |
| Common StockF1,F4 | Jan 10, 2018 | S | 2,200 | $164.129 | D | 1,074,912 | D | |
| Common StockF1,F5 | Jan 10, 2018 | S | 15,496 | $164.9718 | D | 1,059,416 | D | |
| Common StockF1,F6 | Jan 10, 2018 | S | 304 | $165.5318 | D | 1,059,112 | D | |
| Common Stock | Jan 11, 2018 | M | 18,000 | $38.795 | A | 1,077,112 | D | |
| Common StockF1,F7 | Jan 11, 2018 | S | 2,160 | $167.0283 | D | 1,074,952 | D | |
| Common StockF1,F8 | Jan 11, 2018 | S | 15,840 | $168.0274 | A | 1,059,112 | D | |
| Common Stock | holding | — | — | — | 98,000 | I | by Ayers Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F10,F9 | $38.795 | Jan 9, 2018 | M | 18,000 | D | — | Feb 13, 2018 | Common Stock | 18,000 | 94,000 | D |
| Non-Qualified Stock Option (right-to-buy)F10,F9 | $38.795 | Jan 10, 2018 | M | 18,000 | D | — | Feb 13, 2018 | Common Stock | 18,000 | 76,000 | D |
| Non-Qualified Stock Option (right-to-buy)F10,F9 | $38.795 | Jan 11, 2018 | M | 18,000 | D | — | Feb 13, 2018 | Common Stock | 18,000 | 58,000 | D |
Explanation of responses
- F1Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F10Not applicable.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $164.35 to a high of $165.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $165.355 to a high of $165.93 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sales price of the shares sold ranging from a low of $163.50 to a high of $164.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5Represents the weighted average sales price of the shares sold ranging from a low of $164.51 to a high of $165.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6Represents the weighted average sales price of the shares sold ranging from a low of $165.53 to a high of $165.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F7Represents the weighted average sales price of the shares sold ranging from a low of $166.60 to a high of $167.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F8Represents the weighted average sales price of the shares sold ranging from a low of $167.6001 to a high of $168.25 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F9Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.